TheraTarget Inc, incorporated as a spin-off company from the University of Utah and the USTAR Initiative, is a biopharmaceutical drug delivery company developing a variety of customized, synthetic polymer-drug conjugates. Their process utilizes nanopolymer drug delivery technologies developed by the firm. TheraTarget has expertise in creating polymer drug-carrier systems that effectively deliver drugs via the blood stream to treat various forms of cancer through a solid tumor targeted approach. Another approach is called silk-elastinklike protein polymer (SELP), which acts both as an embolizing agent and as a drug delivery depot for a chemotehrapeutic.
